HomeCompareKKPCF vs CHD

KKPCF vs CHD: Dividend Comparison 2026

KKPCF yields 5.04% · CHD yields 1.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KKPCF wins by $40.8K in total portfolio value
10 years
KKPCF
KKPCF
● Live price
5.04%
Share price
$26.00
Annual div
$1.31
5Y div CAGR
25.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$67.1K
Annual income
$13,096.91
Full KKPCF calculator →
CHD
CHD
● Live price
1.27%
Share price
$93.91
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,292.51
Full CHD calculator →

Portfolio growth — KKPCF vs CHD

📍 KKPCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKKPCFCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KKPCF + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KKPCF pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KKPCF
Annual income on $10K today (after 15% tax)
$428.27/yr
After 10yr DRIP, annual income (after tax)
$11,132.37/yr
CHD
Annual income on $10K today (after 15% tax)
$107.94/yr
After 10yr DRIP, annual income (after tax)
$1,098.63/yr
At 15% tax rate, KKPCF beats the other by $10,033.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KKPCF + CHD for your $10,000?

KKPCF: 50%CHD: 50%
100% CHD50/50100% KKPCF
Portfolio after 10yr
$46.7K
Annual income
$7,194.70/yr
Blended yield
15.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

KKPCF
No analyst data
Altman Z
4.9
Piotroski
2/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+4.8% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KKPCF buys
0
CHD buys
0
No recent congressional trades found for KKPCF or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKKPCFCHD
Forward yield5.04%1.27%
Annual dividend / share$1.31$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR25.2%23.1%
Portfolio after 10y$67.1K$26.4K
Annual income after 10y$13,096.91$1,292.51
Total dividends collected$40.8K$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: KKPCF vs CHD ($10,000, DRIP)

YearKKPCF PortfolioKKPCF Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$11,331$630.82$10,856$156.32+$475.00KKPCF
2$12,960$836.34$11,811$195.24+$1.1KKKPCF
3$14,987$1,119.33$12,883$244.38+$2.1KKKPCF
4$17,550$1,514.52$14,091$306.64+$3.5KKKPCF
5$20,854$2,075.26$15,463$385.88+$5.4KKKPCF
6$25,199$2,885.36$17,033$487.17+$8.2KKKPCF
7$31,043$4,079.59$18,843$617.36+$12.2KKKPCF
8$39,096$5,880.43$20,947$785.72+$18.1KKKPCF
9$50,499$8,665.70$23,419$1,004.91+$27.1KKKPCF
10$67,131$13,096.91$26,350$1,292.51+$40.8KKKPCF

KKPCF vs CHD: Complete Analysis 2026

KKPCFStock

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

Full KKPCF Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this KKPCF vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KKPCF vs SCHDKKPCF vs JEPIKKPCF vs OKKPCF vs KOKKPCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.